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This paper reviews intriguing recent findings on the
mechanisms of drug induced hearing loss caused by two
major classes of therapeutic agents: the aminoglycoside
antibiotics and cisplatin. Both drug categories are
nephrotoxic as well as ototoxic. Aminoglycosides and
cisplatin target the outer hair cells in the basal turn of the
cochlea to cause high frequency sensorineural hearing loss in
a substantial percentage of patients treated with these drugs.
Each group of agents appears to generate reactive oxygen
species within the cochlea that trigger downstream
mechanisms leading to cell death. Various protective agents
including antioxidants show promise in protecting the inner
ear from damage in experimental animals. The only
successful double-blind, placebo controlled clinical trial using
a protective agent to prevent ototoxicity was carried out in
China. Aspirin or placebo was given in combination with
gentamicin. A significant decrease in hearing loss was
observed. Successful clinical implementation of protective
agents will require a cautious approach, so that the
therapeutic effect of the anti-infective agent or anti-
neoplastic drug is not attenuated. This may require novel
methods of administration of protective agents, such as
injection within the middle ear. This would provide a
maximal dose of protective agent without systemic
interference with the desired effect of the ototoxic agent.
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Ototoxicity is the functional impairment and cellular
degeneration of the tissues of the inner ear caused by
therapeutic agents. The result of exposure to these agents is a
loss of hearing and/or vestibular function. The most common
ototoxic drugs in clinical use include: aminoglycoside
antibiotics, platinum-based chemotherapeutic agents
(cisplatin and carboplatin), loop diuretics, macrolide
antibiotics, and antimalarials.1 This mini review will be
limited to the ototoxicity of aminoglycoside antibiotics and
cisplatin, because both groups of drugs can cause the most
severe and irreversible hearing loss and also cause severe
nephrotoxicity.
AMINOGLYCOSIDE OTOTOXICITY
Background
Aminoglycoside antibiotics are used clinically for treating
diseases, such as tuberculosis, and those produced by aerobic
Gram-negative bacteria (such as bacterial endocarditis,
urinary tract infections, pneumonia). However, the use of
these agents has declined, especially in developed countries,
because of their significant toxicities and the availability of
better alternatives on the market. The incidence of hearing
loss reported ranges from a few percent up to 33% and
vestibular toxicity occurs in about 15% of patients adminis-
tered aminoglycosides.2 These drugs are still widely used in
developing countries, because they are cost effective, are less
regulated by prescription only sale, and have resulted in
significantly higher incidences of drug toxicity.2 The
increased toxicities seen in these countries could be a result
of increased use in multidrug-resistant tuberculosis requiring
long-term therapy and other infections, over the counter
availability and poor monitoring of auditory function
following over the course of treatment.2
The first member of the aminoglycoside class, strepto-
mycin, was isolated from Streptomyces griseus by Waksman and
co-workers between 1939 and 1944. Other members of this
group include natural products, such as neomycin, kana-
mycin, gentamicin, tobramycin, and semisynthetic products,
such as netilmicin and amikacin. These agents are bacteri-
cidal and produce their therapeutic action by inhibiting
bacterial protein synthesis. Aminoglycosides bind to the
bacterial 30S ribosomal subunit and block initiation of
protein synthesis, cause misreading of the mRNA, or facilitate
premature termination of ongoing translation of mRNA
template.
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Clinical and experimental aspects of aminoglycoside
ototoxicity
The clinical benefits of these agents are counterbalanced by
significant toxicities, affecting the cochlea, vestibular appa-
ratus, and the kidney. Individual aminoglycosides differ in
their ability to produce cochlear versus vestibular toxicity.
Cochlear damage is generally observed with the use of
amikacin, kanamycin, and neomycin, whereas the use of
streptomycin and gentamicin is associated with vestibular
toxicity. Tobramycin is equally effective at producing both
ototoxicity and vestibular toxicity. The aminoglycosides
rapidly enter the cochlea after systemic administration, but
the distribution within inner ear tissues does not correlate
with their preferential toxicity to particular cells in the
cochlea and vestibular system.3 Drug accumulation within
the inner ear does not seem to occur. The inner ear
concentration of aminoglycosides does not exceed that of
the plasma.4 However, it is interesting to note that the
aminoglycosides persist in the inner ear tissues for 6 months
or longer after administration.5 This finding may explain the
enhanced susceptibility of patients to the ototoxicity of
aminoglycosides when they have a history of previous
aminoglycoside therapy.
Prolonged exposure of the cochlear cells to aminoglyco-
sides is apparently linked to the killing of outer hair cells in
the organ of Corti and type I sensory hair cells in the
vestibular organ, leading to permanent hair cell loss and
vestibular damage. Damage to the hair cells progresses from
the base of the cochlea (an area for high frequency sound
detection) to the apex (an area for low frequency sound
detection).2 This is followed by retrograde damage to the
auditory nerve. The degree of hair cell damage and hearing
loss is directly proportional to the dose of the drug to which
the hair cells are exposed. Repeated exposure to aminoglyco-
sides leads to an additive damage to hair cells and other
structures and subsequently to deafness. Damage is more
significant in the elderly who may have fewer hair cells at the
beginning of treatment or lower endogenous protective
mechanisms or in other individuals with compromised
auditory function. In addition, damage may be potentiated
by the concurrent administration of diuretics, such as
ethacrynic acid and furosemide, which produce reversible
hearing loss by themselves. Individuals with renal insuffi-
ciency are more susceptible to aminoglycoside ototoxicity,
because of reduced renal excretion that can result in higher
serum levels and prolonged half-life. This could lead to
increased exposure of the inner ear to toxic concentrations of
aminoglycosides resulting in more severe hearing loss.
Mutations in the mitochondrial 12S ribosomal rRNA
renders patients highly susceptible to aminoglycoside oto-
toxicity. The first described mutation was an A1555G
mutation in the 12S rRNA. Mutations in the mitochondrial
12S ribosomal RNA in humans make this mammalian RNA
more similar to the bacterial ribosomal RNA, the primary
target of the bactericidal activity of aminoglycosides.6 This
mutation has been associated with spontaneous, as well as
aminoglycoside-induced hearing loss. Persons with this
mutation may incur hearing loss after a single dose of
aminoglycoside. It is interesting to note that the vestibular
system is not affected by aminoglycosides in patients with
this mutation. In China, where this mutation appears to
occur in 5–6% of sporadic patients, approximately one-third
of patients with aminoglycoside ototoxicity appear to have
the A1555G mutation.6
Mechanisms of aminoglycoside ototoxicity
Several reports have concluded that the generation of reactive
oxygen species (ROS) is linked to ototoxicity.2 The genera-
tion of ROS involves the formation of an aminoglycoside-
iron complex, which catalyzes their production from
unsaturated fatty acids.7 ROS are believed to promote
apoptotic and necrotic cell death2 (Figure 1a). A critical role
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Figure 1 | Mechanisms of aminoglycoside and cisplatin-induced
outer hair cell death. (a) Aminoglycoside (AG) entry into outer hair
cell results in cell death by either caspase-dependent or caspase-
independent mechanisms. The steps that appear to be involved
include: (1) aminoglycoside entry into outer hair cell through the
mechano-electrical transducer channels; (2) formation of an AG-iron
complex can react with electron donors, such as arachidonic acid
(AA) to form ROS, like superoxide, hydroxyl radical, and hydrogen
peroxide; (3) ROS can then active JNK, which can then (4) translocate
to the nucleus to activate genes in the cell death pathway; (5) these
genes can then translocate to the mitochondria, causing (6) the
release of cytochrome c (cyt c), which can trigger (7) apoptosis via
caspases. Cell death may also result from caspase-independent
mechanisms. (b) Cisplatin (CP) entry into outer hair cell results in cell
death, which appears to be primarily caspase-dependent. The steps
that may be involved include: (1) CP entry into the outer hair cell
through mechanotransducer channels; (2) CP within cells can be
aquated to form the monohydrate complex (MHC), which is more
highly reactive; (3) CP and/or MHC can activate NOX-3, resulting in
ROS production; (4) ROS may, in turn, activate JNK; (5) these
molecules can translocate to the cell nucleus to activate genes
involved in the cell death pathway; (6) these genes can then
translocate to the mitochondria, causing (7) the release of cyt c,
which can trigger (8) apoptosis via caspase-dependent mechanisms.
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of ROS in aminoglycoside ototoxicity is supported by the
observation that animals overexpressing the superoxide
scavenging enzyme, superoxide dismutase, demonstrate less
aminoglycoside-induced ototoxicity compared with the wild-
type controls.8 One signaling pathway activated by amino-
glycosides via ROS is the c-Jun N-terminal kinase (JNK)
pathway and contributes to cell apoptosis.9 Inhibition of JNK
protected the cochlea from neomycin-mediated ototoxi-
city,10–12 suggesting that this pathway is critical in inducing
hair cell death. One of the downstream targets of the JNK is
the transcription factor, activating protein-1. Gentamicin
treatment of cochlear explants results in increased activating
protein-1 activity in the outer hair cells. The main
component of the activating protein-1 complexes was found
to be the c-Fos protein, which was found only in gentamicin-
treated explants and not in controls.13
A recent study has also indicated a role of the transcription
factor, nuclear factor-kB in mediating cytoprotection against
kanamycin-induced ototoxicity.14 These investigators demon-
strated that the death of mouse outer hair cells following
kanamycin administration was associated with a loss of p65 and
p50 labeling in the nucleus, whereas immunolabeling of these
two subunits of nuclear factor-kB was observed in the surviving
inner hair cells. Mice given protective agents in combination
with kanamycin were found to have preservation or outer hair
cells in the basal turn. These cells exhibited a greater expression
of nuclear factor-kB than controls.
Otoprotective approaches to preventing aminoglycoside
toxicity
Aminoglycosides can react with iron to generate ROS.
Protection against ototoxicity may be achieved by reducing
the availability of iron using chelators, such as deferoxamine
and dihydroxybenzoate. This leads to a dramatic reduction of
aminoglycoside ototoxicity. Importantly, these iron chelators
do not interfere with the therapeutic efficacy of the
aminoglycosides.2 Another approach to protect the cochlea
is to administer antioxidants. Antioxidants, which show
protection against aminoglycoside ototoxicity in experimen-
tal animals, include lipoic acid, d-methionine, salicylates, and
dihydroxybenzoate (for review see Lesniak et al.7).
Another drug of this class is aspirin or sodium salicylate.
A recent double-blind trial in China has demonstrated that a
14 day administration of aspirin attenuates gentamicin ototoxi-
city.2 The incidence of hearing loss in patients administered
gentamicin and placebo was 13%, whereas in patients
administered gentamicin and aspirin showed a 3% incidence
of hearing loss was observed. The dose of aspirin used caused
gastrointestinal complications in 3/92 patients. Gastric
bleeding was confirmed in each case by endoscopy and these
patients were removed from the study. These complications
may have been reduced or eliminated if enteric-coated aspirin
had been used or if the patients were treated with proton
pump inhibitors.2 Salicylates are both iron chelators and free
radical scavengers. These actions may partially explain the
protective effect of aspirin in this clinical trial.
CISPLATIN OTOTOXICITY
Background
Cisplatin is a widely used chemotherapeutic agent for the
treatment of various malignancies, including testicular,
ovarian, bladder, cervical, head and neck, and non-small cell
lung cancers. The mechanism of antitumor action of cisplatin
involves uptake by the cancer cell; aquation within the tumor
cell, which makes the drug more reactive for cellular targets;
then, the platinum atom of cisplatin forms covalent bonds
with DNA at the N7 positions of purine bases to form
intrastrand and interstrand crosslinks. A number of down-
stream signaling pathways can then be activated to cause
DNA-damage. These can include MAPK/JNK/ERK pathways.
Cell death in tumor cells is primarily through apoptosis,
although in vitro tumor cells may undergo necrosis when
exposed to high concentrations of cisplatin.15
The use of this agent is limited by nephrotoxicity,
neurotoxicity, and ototoxicity. Cisplatin ototoxicity is
manifested by sensorineural hearing loss, which can be
severe to profound after high-dose chemotherapy.16 Cispla-
tin-related hearing loss is usually bilateral and appears first at
high frequencies. Progression to lower frequencies may occur
with continued therapy.
Some audiometric studies have reported elevated hearing
thresholds in 75–100% of patients.16 There is substantial
variability in susceptibility to the ototoxic effects of cisplatin.
Risk factors include: rapid intravenous bolus injections; high
cumulative doses; pre-existing hearing loss; renal insuffi-
ciency; anemia; hypoalbuminemia; and prior cranial irradia-
tion. Cisplatin ototoxicity appears to be related to age of the
patient. Both elderly and pediatric patients are reportedly
more sensitive to cisplatin ototoxicity. Li et al.17 demon-
strated that pediatric patients under 5 years of age are most
susceptible. They developed a logistic regression model that
predicted that about 40% of children fewer than 5 years of
age would develop a moderate to severe hearing loss after a
cumulative dose of 400 mg/m2 as opposed to a 5% risk in
children between 15 and 20 years of age.17
There may be genetic factors that make patients more
sensitive to cisplatin ototoxicity. A recent study of survivors
of testicular cancer who received cisplatin chemotherapy
showed differences in functional polymorphisms in glu-
tathione-S-transferase. The presence of both alleles of 105Val-
GSTP1 appeared to offer protection against hearing loss from
cisplatin. The risk of having a poor hearing result was more
than four times higher in patients with 105Ile/105Ile-GSTP1
or 105Val/105Ile-GSTP1. Those genotypes associated with
poor hearing after cisplatin therapy could indicate a limited
amount of glutathione available for detoxification of
cisplatin.18
Mechanisms of cisplatin ototoxicity
Cisplatin has been shown to target three areas in the cochlea:
the hair cells in the basal turn of organ of Corti, the spiral
ganglion cells and the lateral wall tissues (spiral ligament and
stria vascularis). Outer hair cells, cells in the stria vascularis,
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and spiral ligament each have been shown to undergo
apoptosis and platinated DNA immunoreactivity has been
localized to the nuclei of outer hair cells, and cells in the stria
vascularis and spiral ligament (reviewed by Rybak et al.16).
ROS mimic the effects of cisplatin on outer hair cells in vitro,
and cisplatin reacts with cochlear tissue explants to generate
ROS. This can lead to calcium influx within cochlear cells
resulting in apoptosis. A unique isoform of nicotinamide
adenine dinucleotide phosphate oxidase, NOX 3 has been
demonstrated in the rat cochlea and is upregulated following
ototoxic doses of cisplatin.19 This can lead to large increases
in superoxide production, which can lead to the formation of
hydrogen peroxide. The latter molecule can be catalyzed by
iron to form the highly reactive hydroxyl radical, which
interacts with membrane polyunsaturated fatty acids for the
highly toxic aldehyde, 4-hydroxynonenal. Superoxide can also
react with nitric oxide to form peroxynitrite, which reacts
with proteins to form nitrotyrosine. Cisplatin-treated ani-
mals were found to have immunoreactivity for 4-hydroxy-
nonenal and peroxynitrite in the cochlea. Antioxidant
defenses in cochlear tissues can be depleted by cisplatin,
allowing ROS to increase. Excessive ROS generated by
cisplatin could overwhelm the antioxidant defense mechan-
isms within the cochlea, activating the apoptotic pathway
causing cell death in outer hair cells16 (Figure 1b).
Otoprotective approaches to the prevention of cisplatin
ototoxicity
Antioxidants have been used to reduce cisplatin ototoxicity in
animal experiments, presumably by scavenging ROS. These
have included D- or L-methionine, N-acetyl-cysteine, sodium
thiosulfate, lipoic acid, ginkgo biloba extract, aminoguani-
dine, alpha-tocopherol, ebselen combined with allopurinol,
and salicylates. A potential problem with the administration
of antioxidants is a reduction in antitumor efficacy of
cisplatin.16 Sodium thiosulfate and N-acetylcysteine are able
to bind covalently to platinum, producing an inactive
complex.16 This can be obviated by intratympanic adminis-
tration of the protective agent, so that its action against
cisplatin will be confined to the cochlea. D-methionine readily
traverses the round window membrane and has been shown
to prevent cisplatin ototoxicity in animals when applied to
the round window membrane before cisplatin.16
Other experimental approaches have included the applica-
tion of inhibitors of the cell death pathway, for example the
p53 inhibitor, pifithrin-alpha, caspase inhibitors, and gene
therapy with adeno-associated virus-mediated delivery of the
X-linked inhibitor of apoptosis protein.16,20 Clinical trials
with amifostine have shown that this drug is not effective in
reducing cisplatin-induced hearing loss (cf 16). No clinical
trials have yet been published to show efficacy of cisplatin
protection.
CONCLUSION
Both aminoglycosides and cisplatin cause a high frequency
hearing loss that is associated with loss of outer hair cells in
the basal turn of the cochlea. It is interesting to note that
these drugs are also nephrotoxic. Both classes of ototoxic
agents can cause the formation of ROS within the cochlea.
The ROS formed can lead to cellular damage and apoptosis,
resulting in hearing loss. The possibility exists that protective
agents could ameliorate or prevent hearing loss from these
drugs. Experimental studies in animals have shown that a
variety of antioxidants can attenuate the ototoxicity of either
aminoglycosides or cisplatin. To date few clinical trials have
investigated the safety and efficacy of administering protec-
tive agents to prevent ototoxicity. Future clinical trials should
examine the appropriate route and timing of administration
of protective agents to determine the optimum method for
preservation of hearing in patients receiving these drugs.
Such routes could include injection of a protective agent into
the middle ear (intratympanic injection) to obtain a high
local concentration of the protective molecule, while sparing
the therapeutic effect of these drugs.
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